(ELV) Elevance Health - Ratings and Ratios

Elevance Health, Inc. is a leading health benefits company in the United States, operating through four distinct segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company provides a comprehensive array of health plans and services to a diverse customer base, including individual, employer group, Medicare, Medicaid, and FEP members. Its extensive offerings encompass health products, administrative managed care services, and specialty insurance products, such as stop loss, dental, vision, and supplemental health insurance benefits.

Beyond its core health benefits business, Elevance Health has a significant presence in the pharmacy services sector, offering a range of services including home delivery, specialty pharmacies, claims adjudication, formulary management, and rebate administration. The company also provides various healthcare-related services and capabilities, including specialty care enablement, behavioral health, palliative care, virtual care, and payment integrity. Its HealthOS platform facilitates clinical data exchange, research, and analytics, while also supporting business process services.

With its operations conducted under prominent brands such as Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon, Elevance Health has established itself as a major player in the US healthcare landscape. The companys rebranding from Anthem, Inc. to Elevance Health, Inc. in June 2022 reflects its evolving business strategy and expanding service portfolio.

Analyzing the and , we observe that ELVs stock is currently trading below its 20-day, 50-day, and 200-day simple moving averages (SMA20, SMA50, SMA200), indicating a potential downtrend. The Average True Range (ATR) of 15.02, representing 3.91% of the last price, suggests moderate volatility. Considering the , ELVs market capitalization stands at $91.23 billion, with a P/E ratio of 15.72 and a forward P/E of 11.70, indicating a relatively attractive valuation. The Return on Equity (RoE) of 13.94% is also noteworthy.

Forecasting the future performance of ELV, we can anticipate that the stock may continue to face downward pressure in the short term, given its current position relative to its moving averages. However, the companys solid fundamental profile, including a reasonable P/E ratio and respectable RoE, could provide a foundation for long-term stability. If the overall healthcare sector experiences a resurgence, ELVs diversified services and prominent brand presence may enable it to capitalize on emerging opportunities, potentially driving the stock price higher. A potential target price could be around $420, representing a 9.5% increase from the current level, based on a reversion to its SMA50. Nevertheless, this forecast is contingent upon various factors, including the overall market environment and the companys future financial performance.